Direct costs of first‐generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 974-976

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patients treated with first‐generation HCV protease inhibitors exhibit high ribavirin concentrations

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 5, 2015-05 ,pp. : 517-524

John Wiley & Sons Inc

Access to resources Recommend Favorite

eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 71-78

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection

By  

HEPATOLOGY, Vol. 61, Iss. 2, 2015-02 ,pp. : 438-447

John Wiley & Sons Inc

Access to resources Recommend Favorite

Organic Anion Transporting Polypeptide‐Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 159-166

John Wiley & Sons Inc

Access to resources Recommend Favorite